Observation on the clinical efficacy of Dapagliflozin combined with Qiliqiangxin capsules in the treatment of chronic heart failure

Objective: To observe the clinical efficacy of dapagliflozin combined with Qili Qiangxin capsules in the treatment of chronic heart failure. Method: Sixty patients with heart failure admitted to our hospital from January 2024 to June 2024 were randomly divided into an observation group and a control group, with 30 cases in each group. The control group received conventional anti heart failure treatment, while the observation group received treatment with dapagliflozin combined with Qiliqiangxin capsules on the basis of the control group. Compare the clinical efficacy, evaluation of cardiac function indicators, and incidence of adverse reactions between two groups. Result: The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). The LVEF of the two groups of patients was higher than before treatment, and the observation group was higher than the control group (P<0.05). The LVESD and LVEDD of both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05). The total incidence of adverse reactions in the observation group and the control group were 10.0% and 13.33%, respectively, and the difference was not statistically significant (P>0.05). Conclusion: The combination of Dapagliflozin and Qili Qiangxin Capsules can effectively improve the heart function of heart failure patients and enhance treatment effectiveness. The combination of the two does not increase the risk of adverse events and has good safety, which is worthy of clinical promotion and application.